Abvc biopharma vitargus® phase ii study received ethical approval at sydney eye hospital in australia

Fremont, ca, may 22, 2023 (globe newswire) -- via newmediawire -- abvc biopharma, inc. (nasdaq: abvc), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, central nervous system (cns) disorders, and ophthalmology, today announced that the vitrargus® phase ii study at the sydney eye hospital in new south wales, australia received ethical approval from the st. vincent's hospital melbourne human research ethics committee (hrec) on may 15, 2023.
ABVC Ratings Summary
ABVC Quant Ranking